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Abstract 
This study was an extension of a previous study done by Spiegel, 
Bruce, Falkin-Gregg, and Nuzzarello (in press), the latter of 
which tested whether cognitive behavior therapy assisted 
alprazolam discontinuation in panic disorder patients. The focus 
of cognitive behavior therapy in relation to benzodiazepine 
discontinuation placed great emphasis on changing cognitive 
biases during th~ treatment process. The present study 
investigated whether groups differed on cognitive factors 
associated with panic disorder (e,g. catastrophic 
misinterpretations, sensitivity to bodily sensations, and a 
feeling of lack of control over emotions and situations) and 
whether that change predicted discontinuation. The results 
showed the alprazolam plus cognitive behavior therapy group had 
significantly greater cognitive change compared to the alprazolam 
only group. Furthermore, cognitive change, in addition to 
overall anxiety, was involved in predicting which subjects were 
able to successfully discontinue alprazolam treatment. 
Implications for benzodiazepine treatment in conjunction with 
cognitive behavior therapy are discussed. 
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The Implications of Cognitive Change 
in the Treatment of Panic Disorder with Agoraphobia 
Panic disorder with agoraphobia (PDA) is extremely 
debilitating, prohibiting the daily functioning of thousands 
of people. It involves feelings of intense fear in 
circumstances when there is nothing to fear. The disorder 
is accompanied by severe attacks of panic which occur out of 
the blue for no apparent reason. Consequently, patients may 
develop an intense fear of that particular situation or 
circumstance. This fear facilitates the development of 
agoraphobia because patients do whatever they can to prevent 
a recurrence of the experience, thereby avoiding many 
aspects of everyday life. According to the Diagnostic and 
Statistical Manual (DSM-III-R), symptoms of panic disorder 
include "shortness of breath or smothering sensations; 
dizziness ... choking ... accelerated heart rate ... shaking; 
sweating; nausea ... hotflashes; chest pain or discomfort; 
fear of dying; fear of going crazy or doing something 
uncontrolled during an attack" (American Psychiatric 
Association, 1987, p. 236). 
The most widely used treatment for PDA is the 
benzodiazepine alprazolam (Xanax). Numerous studies have 
shown that alprazolam effectively controls panic attacks, 
allowing patients to resume normal activities (Ballenger, 
Graham, Burrows, DuPont, Lesser, Noyles, Pecknold, Rifkin, & 
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Swinson, 1988; Barlow, 1988; Rickels, Schweizer, Weiss, & 
Zavodnick, 1993). For example, Ballenger et ale (1988) 
executed a large placebo-controlled study to test the 
efficacy of alprazolam in the treatment of PDA. After three 
weeks of alprazolam treatment, 51% of subjects showed marked 
improvement and at the eight week point, 41% of subjects 
showed moderate improvement. Alprazolam was found to 
effectively decrease the frequency of both spontaneous and 
situational'panic attacks, phobic fears, avoidance behavior, 
anxiety, and secondary disabili~y. Furthermore, the study 
revealed a significantly larger dropout rate for subjects in 
the placebo group (102/234) as compared to the alprazolam 
treated group (21/247). The authors suggested that lithe 
large difference in dropout rates, primarily because of 
ineffectiveness of placebo, was itself, a measure of the 
efficacy of alprazolam" (p. 419). 
Although alprazolam is effective in the acute phase of 
treatment, others note that it creates physical dependency 
and can be extremely hard to discontinue due to withdrawal 
symptoms, such as rebound panic and anxiety (Busto, Sellers, 
Naranjo, Cappell, Sanchez-Craig, Sykora, 1986; Fyer, 
Liebowitz, Gorman, Campeas, Levin, Davis, Goetz, & Klein, 
1987; Noyles, Garvey, Cook, & Suelzer, 1991; Pecknold, 
Swinson, Kuch, & Lewis, 1988; Rickels et al., 1993; 
Schweizer, Rickels, Case, & Greenblatt, 1990) For example, 
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Rickels et al. (1993) reported °a withdrawal syndrome in 
almost all of the 27 alprazolam-treated patients. Also, 33% 
of these patients were unable to successfully discontinue 
their medication" (p. 61). Of those who did discontinue, 
approximately half relapsed within the following months. 
One idea to assist alprazolam discontinuation is to 
combine Cognitive Behavior Therapy (CBT) with alprazolam. 
CST can be focused on altering features of panic disorder in 
order to fac~litate the discontinuation process (Barlow, 
1988; Beck, 1985; Clark, 1986; Klosko, Barlow, Tassinari, & 
Cerny, 1990; Otto, Pollack, Sachs, Reitzer, Meltzer-Brody, & 
Rosenbaum, 1993; Spiegel, Bruce, Falkin-Gregg, & Nuzzarello, 
in press). CBT; places strong emphasis on the personal 
management of problematic anxiety through skill development, 
education, and systematic exposure to feared stimuli 
(Spiegel, et al., in press). Barlow, Craske, Cerny, and 
Klosko (1989) devised a specific form of CBT called Panic 
Control Treatment (PCT) which aims at reducing patients' 
fear of the bodily sensations which they associate with 
panic. Cognitive change is one area emphasized by CBT and 
many have hypothesized that successful discontinuation 
requires change in this dimension. For example, Otto et al. 
(1993) reported that 13 of 17 (76%) patients receiving CBT 
successfully discontinued benzodiazepine treatment compared 
to those receiving only slow taper (four of 16; 25%). They 
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speculated that their intervention "decreased fears and 
catastrophic misinterpretations of emergent panic sensations 
and withdrawal symptoms ... " (p. 1489). 
Patients with PDA suffer from a variety of cognitive 
dysfunctions. Specifically, one dysfunction of the disorder 
is the catastrophic misinterpretation of anxiety symptoms or 
situations. When feeling nervous, many patients often 
catastrophize about the outcome of their situation (Beck, 
1985; Chambless, Caputo, Bright, & Gallager, 1984; Clark, 
1986; Goldstein & Chambless, 1918). Clark (1986) explains 
that the stimuli which these patients misinterpret can be 
external or internal. If the original stimuli is external, 
such as a ballgame where a panic attack has previously 
occurred, then the patient experiences anticipatory anxiety 
of having another panic attack in this situation, and thus 
avoids the ballgame. However, the stimuli could also be an 
internal bodily sensation, like sweating or trembling. 
Here, the sweating will cause anxiety and perhaps the fear 
of losing control and having a stroke. If these bodily 
sensations are misinterpreted to be catastrophic, further 
anxiety occurs and the cycle continues, resulting in a panic 
attack. As a result, sufferers will avoid situations which 
may provoke these internal sensations. 
The Agoraphobic Cognitions Questionnaire (ACQ) measures 
catastrophic misinterpretations and the way patients predict 
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the outcome of events. The directions instruct the patient 
to respond according to how they feel when nervous or 
frightened. It is a 14-item test in which each patient 
rates the items on a 5-point scale ranging from 1 (thought 
never occurs) to 5 (thought always occurs when I am 
nervous). The ACO is two-factor. It emphasizes 
Social/Behavioral Concerns (i.e. acting foolish, babbling or 
talking funny), and Physical Concerns (i.e. heart attack, 
going blind}. (Chambless, et al., 1984; Chambless & 
Gracely, 1989). Chambless et al. (1984) have determined 
that the ACQ is internally consistent (Cronbach's alpha = 
.80) and has good test-retest reliability. 
Another important cognitive aspect associated with panic 
disorder 1s the patients' sensitivity to anxiety sensations 
which they feel will inevitably result in catastrophic 
situations, such as medical catastrophe, embarrassment, or 
death (McNally & Lorenz, 1987; Reiss, Peterson, Gurskey, & 
McNally, 1986). For example, when feeling an increase in 
heart rate, a patient may predict a heart attack. Being 
anxiety sensitive, which is prevalent among panic disorder 
patients, will cause them to be keenly aware of sensations 
and avoid potential anxiety-provoking situations (McNally & 
Lorenz, 1987; Reiss et al., 1986). 
The Reiss-Epstein-Gursky Anxiety Sensitivity Index (ASI) 
is a questionnaire designed specifically to measure the fear 
..
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of bodily sensations so commonly found among panic disorder 
patients. The ASI is a 16-item test which centers on a 
variety of aversive consequences which may result from an 
anxiety provoking stimuli (i.e. It scares me when my heart 
beats rapidly) (Barlow, 1988; McNally & Lorenz, 1987; Reiss 
et a1., 1986). The patient responds on a scale from 0 
(strongly disagree) to 5 (strongly agree). Reiss et a1. 
(1986) found tpe ASI to have sound psychometric properties 
and an adequate test-retest reliability. The ASI 
distinguishes itself from other,anxiety tests in that it 
measures the "fear of anxiety symptoms, rather than the 
frequency or the intensity of these symptoms" (McNally & 
Lorenz, 1987, p. 4). Reiss et a1. (1986) claim that the ASI 
is specifically correlated with panic disorder and 
agoraphobia and is a better predictor of fearfulness 
compared to other anxiety scales. 
In addition to catastrophic misinterpretations and 
sensitivity to bodily sensations, one of the most ubiquitous 
features of panic disorder patients is their fear of losing 
control. Patients often feel that when something negative 
happens to them, whether it be external or internal, it can 
not be stopped or controlled (Barlow, 1988; Craske, Bunt, 
Rapee, & Barlow, 1991; Sanderson, Rapee, & Barlow, 1989). 
An empirical example of the role of perceived control was 
conducted by Sanderson et al. (1989). They used C02 to 
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induce lightheadedness in twenty panic disorder patients and 
compared those who believed they had control over the amount 
of C02 they were receiving, and those who did not. They 
found that the group who felt they had control over the 
amount of C02 enriched air they were receiving reported a 
fewer number of DSM-III-R related panic symptoms, had fewer 
catastrophic cognitions, and reported overall less anxiety 
than the patients who felt they had no control over the 
amount of C02 enriched air they were breathing. This 
suggests that the probability of having a panic attack 
decreased as the sense of control increased. 
In order to measure patients' perceived level of 
emotional control the Emotional Control Questionnaire (ECQ) 
was developed (Rapee, Craske, & Barlow, 1989). The ECQ 
consists of a 15 item questionnaire with statements such as, 
"I can con~rol ~he degree to which I react to particular 
situations. When I am put under stress, I am likely to lose 
control. w The patients respond on a 6-point scale from 0 
(Strongly Disagree) to 5 (Strongly Agree). The ECQ has 
proven to have good test-retest reliability, construct 
validity, and internal consistency. Higher scores are an 
indication that the patient perceives more control over his 
emotions (Rapee, et al., 1989). 
While adding CBT to alprazolam treatment has been 
successful in facilitating discontinuation, we still do not 
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know whether this is predicted by or corresponds with 
cognitive change. Catastrophic misinterpretations, lack of 
emotional control, and anxiety sensitivity are just a few of 
the cognitive aspects hypothetically involved in panic 
disorder. For example, a patient who becomes less sensitive 
to internal sensations during treatment, as measured by the 
ASI, may be less likely to catastrophize about these 
internal situations which may arise again during the taper 
process and·after discontinuation. It would by very 
beneficial to determine if cogn~tive change in any of these 
areas can predict who successfully discontinues drug 
therapy. 
The following study is an extension of a study done by 
Spiegel, Bruce, Falkin-Gregg, & Nuzzarello (in press) which 
compared the combination of CBT and alprazolam to an 
alprazolam only group. The original study involved 20 
patients with chronic panic disorder, whose panic attacks 
had responded to treatment with alprazolam. Each subject 
underwent slow, flexible drug taper with or without 
concurrent cognitive behavior therapy. Results showed that 
85% of the subjects were able to successfully discontinue 
pharmacotherapy. However, during the following three 
months, 60% of those who had been tapered with only 
supportive medical management (without CBT) relapsed, 
compared with none who had received cognitive behavior. The 
-11 
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present study attempted to determine: 1) If the addition of 
cognitive behavior therapy to alprazolam treatment resulted 
in more cognitive change than with the drug alone, and 2) 
Is the cognitive change which occurred from pre-treatment to 
post-treatment, as measured by the ECO, ASI, and ACO, 
involved in predicting successful long-term discontinuation 
of a1prazo1am. 
It was pre~cted that the group receiving both a1prazo1am 
and CBT will have more cognitive change than the drug only 
group because CBT works at teac~ing patients to deal with 
somatic sensations and can alter their catastrophic 
misinterpretations (Otto et a1., 1993). It was also 
hypothesized that changes in the ACO, ASI, and ECO scores 
may be involved in predicting successful vs. unsuccessful 
, 
discontinuation because these scales emphasize the cognitive 
aspects associated With panic disorder. These results would 
support the notion that altering distorted cognitions 
prepares sUbjects to deal with the recurring symptoms which 
often arise during and after drug taper. 
METHOD 
Subjects 
Subjects met the DSM-III-R criteria for panic disorder 
with agoraphobia of at least 6 months duration. They were 
recruited by the University of Illinois Anxiety Disorders 
Clinic at Peoria to participate in a alprazo1am 
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discontinuation study. Subjects consisted of 4 males and 16 
females totaling 20 subjects. Ages ranged from 26-51 with a 
mean age of 38 years. 
Design and Procedures 
After screening, subjects were stabilized on alprazolam 
for a 2 week duration. Following a two-week baseline 
period, subjects were randomly placed into two treatment 
groups:alpra~lammaintenance and taper with supportive 
medical management (A-Only, N=lO), or the same treatment 
plus cognitive behavior therapy, (A+CBT, N=lO). The protocol 
was approved by the Institutional Review Board of the 
college, and all subjects gave informed consent and agreed 
to random assignment. 
Pharmacotherapy. Alprazolam maintenance and taper were 
carried out identically in both groups and consisted of two 
phases: a stable-dose phase, during which subjects were 
maintained on therapeutic doses; and a taper phase of 
variable length, during which alprazolam was decreased every 
7-14 days until either discontinuation was complete or the 
subject declined to reduce the dose any further. During the 
pharmacotherapy, the subjects met weekly with a 
psychiatrist, who was blind to the particular group 
assignment, for supportive medical management. Taper was 
done gradually in attempt to limit withdrawal symptoms. 
Cognitive Behavior Therapy. The alprazolam plus CBT 
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group differed solely from the alprazolam only group in that 
sUbjects received a form of CBT (Panic Control Treatment) 
designed by Barlow and Craske. It was administered to 
subjects individually in 12 weekly sessions in accordance 
with written manuals. The therapy incorporated the 
following components: education about panic disorder, 
training in slow, diaphragmatic breathing, cognitive 
restructuring,. and interoceptive exposure (i.e., exposure to 
feared bodily sensations). 
Measures 
Experienced clinician- and self-ratings were made at pre­
treatment baseline (the two weeks following drug 
stabilization),: 2 weeks post-treatment (two weeks after the 
last successful taper step), and a IS-weeks post-treatment. 
The evaluator was blind to the subjects' group aSSignment. 
Anxiety sensitiVity. The Anxiety Sensitivity Index was 
used to assess sensitivity to anXiety sensations (ASI, 16 
items, 0-80 total score, Reiss et al., 1986). (See Appendix 
A) 
Catastrophic Cognitions. Catastrophic 
misinterpretations due to experiencing anxiety were assessed 
by the Agoraphobic Cognitions Questionnaire (ACQ, 15 items, 
0-5 total average score, Chambless, et al., 1984). (See 
Appendix B) 
Emotional Control. Subjects' beliefs about the control 
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they have over anxiety and their emotions was assessed by 
the Emotional Control Questionnaire (ECQ, 18 items, 0-75 
total sum score; Rapee et al., 1989). (See Appendix C) 
Phobic Avoidance. Level of agoraphobia rated by each 
subject was assessed using the Mobility Inventory for 
Agoraphobia (MIA, 27 items, 1-5 total average score; 
Chambless, et. aI, 1984). 
Depressed MQod. The Beck Depression Inventory (BDI) was 
used to assess level of depression. It contains 21 items 
and a 0-63 total sum score (Bec~, Ward, Mendelson, Mock, & 
Erbaugh, 1961). 
Anxious Mood. The Hamilton Anxiety Rating Scale consists 
of 14 items with a 0-56 total sum score (Hamilton, 1959). 
It was used to measure general anxiety. 
Panic Attacks and Anticipatory Anxiety. The Sheehan 
Panic and Anticipatory Anxiety Scale (Sheehan, Coleman, 
Greenblat, Jones, Levine, Orsulak, Peterson, Schildkraut, 
Uzogara, & Watkins, 1984) was used by the clinician to rate 
the frequency, intensity, and duration of anticipatory 
anxiety and spontaneous, situational, limited symptoms (less 
than 4 symptoms), and full panic attacks (greater than or 
equal to 4 symptoms). Self-reports of these same dimensions 
were assessed using daily diaries which were administered 
two weeks prior to each major assessment point. 
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The data of 20 panic disorder patients was reviewed and 
analyzed using Analyses of Covariance (ANCOVA) with the pre­
treatment scores as the covariate, to check for significant 
differences between the two groups at two-weeks post-taper 
and 15-week follow up. In addition, the change in scores on 
all measures were computed and analyzed using Stepwise 
Logistic Regression (SPSS PC+). The study also determined 
which, if any"measures predicted who successfully 
discontinued a1prazo1am treatment. 
RESULTS 
Results of theANCOVAs are depicted in Table 1 along with 
each groups' mean test scores at baseline, two-weeks post­
taper and 15-weeks post-taper. At 2-weeks post-taper, a 
significant difference between the two groups existed on the 
following measures: Disability (Clinician-Rated Disability 
Scales; p<.04), Anticipatory Anxiety Frequency (Sheehan 
Panic and Anticipatory Anxiety Scale; p<.02), Catastrophic 
Thinking (ACQ; p<.003), and Emotional Control (ECQ; p<.04). 
At two-weeks post-taper the a1prazo1am plus CBT group showed 
significantly more improvement on everyone of these 
measures. ANCOVAS performed at 15-weeks post-taper revealed 
significant differences in Anticipatory Anxiety Intensity 
(Sheehan Panic and Anticipatory Anxiety Sca1e;p<.03), 
Anxious Apprehension, Anxiety (Hamilton Anxiety Rating 
Scale; p<,03), and Depression (Beck Depression Inventory; 
16 
Cognitive Change 
p<.04) as well. 
Insert Table 1 about here 
Logistic Regression Analyses were used to test if pre­
treatment to post-treatment change in any dependent measure 
predicted discontinuation outcome. The entry criteria used 
was .05 while the exit criteria was conservatively set at 
.10. Resu1~s showed that only two variables significantly 
predicted the outcome. The pre~treatment to post-treatment 
change in the ASI and the Hamilton Anxiety Rating Scale 
(HAT) were the two variables which the model retained. 
Specifically, the results showed that a pre-treatment to 
post-treatment decrease in scores on the ASI and the HAT 
predicted successful discontinuation whereas no change 
predicted failure. The combination of the two correctly 
classified 85% of patients. 
The major goal of the regression model was to predict 
group membership, which did successfully occur. The Model 
Chi Square was used to test the significance of the model 
and was significant at .0008. In addition to the predictive 
value of the ASI and the HAT, when the ASI was removed, the 
ACO and HAT classified 80% of the subjects correctly, 
indicating the ACO was also a good predictor of 
discontinuation success. 
17 
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DISCUSSION 
As early as two weeks following drug taper, subjects in 
the alprazolam only group were showing significantly 
different scores than the combination group on a variety of 
measures. In particular, the results confirmed the proposed 
hypothesis that the alprazolam plus CST group would have 
significantly more cognitive change than the alprazolam only 
condition. The subjects receiving alprazolam only were 
continuing to catastrophize and were more likely to 
underestimate perceived levels of control as measured by the 
ACO and ECO, respectively. They also anticipated more 
anxiety which had a distinct disabling effect on their 
lives. These differences between the groups at two-weeks 
post-taper were the first indications that perhaps the group 
receiving CBT experienced a cognitive restructuring, helping 
them to deal with the recurring symptoms after drug taper. 
In addition to the cognitive differences between the two 
groups at two-weeks post-taper, by IS-weeks post-taper the 
subjects in the alprazolam only condition were experiencing 
an overall anxious mood and a higher level of depression 
than the subjects in the combination group. It appears as 
though a cycle developed as the drug only subjects completed 
the taper process. As follow-up progressed without any 
cognitive change, they did not know how to deal with the 
recurring symptoms, such as rebound panic and anxiety. As a 
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result, they began catastrophizing again, became more 
anxious, and perceived a lower level of emotional control. 
By IS-weeks post-taper, the alprazolam only subjects were 
significantly more anxious and depressed. In addition, 60% 
of this group went back on medication. 
These results supported the first hypothesis that more 
cognitive change would occur in the alprazolam plus CBT 
condition than in the alprazolam only group. Because this 
change occu~red during treatment, CBT subjects may have been 
better prepared to deal with recurring symptoms after 
alprazolam was discontinued. Furthermore, this implies that 
CBT is an important factor involved in facilitating 
cognitive restr~cturing during panic disorder treatment. 
The second hypothesis offered that perhaps a lack of 
change on the cognitive measures (ASI, ACO, and ECO) during 
treatment would be a significant predictor of relapse. 
Logistic Regression Analyses partially supported this 
hypothesis by revealing that the ASI and the Hamilton 
Anxiety Rating Scale (HAT) had significant importance in 
determining treatment outcome, despite their uninvolvement 
with the first hypothesis. Change in scores on the ASI and 
the HAT were found to be most associated with predicting 
successful discontinuation. Clinically, this means the 
patients who were still keenly sensitive to their bodily 
sensations and who were experiencing an overall anxious mood 
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at two-weeks post-taper were the ones who relapsed. 
Seemingly, successful discontinuation required cognitive 
change in these two areas. 
In addition to the role of the ASI, the ACQ, when used 
with the HAT, correctly classified the subjects 80% of the 
time. This suggests that the ACQ does have some predictive 
value. Perhaps it was not more strongly correlated with 
discontinuatiop success as was predicted because it measures 
general catastrophic thinking and the subjects' symptoms 
were more specified. Like this,measure, the ASI also tests 
for catastrophic thinking, but it is specific to bodily 
sensations. This proposes that anxiety sensitivity is a 
target point that needs to be addressed when treating panic 
disorder patients, either through CST or another means. The 
other target point is anxious mood. At two-weeks post­
taper, the subjects who were still experiencing a general 
anxiety and edginess, in addition to being anxiety 
sensitive, were likely to go back on alprazolam treatment. 
Although this hypothesis was only partially supported, 
the results and implications are encouraging. First, the 
findings imply that CST is responsible for the significant 
decrease in anxiety sensitivity as reflected by the lower 
scores on the ASI for the SUbjects in the combination group 
compared to the alprazolam only subjects. While this study 
does imply this correlation, further research is necessary 
20 
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to conclude the implication. One recommendation is to do 
the same type of discontinuation study using a normal 
version of CST and a form of CST which is controlled for all 
else except anxiety sensitivity. This research could 
investigate the existence of the correlation between CST and 
anxiety sensitivity suggested by this study. 
Another interesting result revealed that four alprazolam 
only subjects showed a decrease in scores on the ASI and the 
HAT, and successfully discontinued medication. Unlike 
previous suggestions, this impl~es that there may be other 
ways, besides structured CST, to alter cognitions and 
anxiety during benzodiazepine treatment. Perhaps, a self­
help mechanism which employs relaxation training and 
cognitive restructuring would be just as effective as full 
blown CBT. The fact that four patients did their own CST 
without any prior instruction proposes that changing 
cognitions and anxious mood may be considerably less complex 
than previously expected. This study opens new avenues 
regarding effective agencies for altering dysfunctional 
cognitions. Further research can be aimed at looking for 
other mechanisms by which to alter the dysfunctional 
cognitions of panic disorder patients. 
Surprisingly, although change in ASI predicted relapse, 
it failed to show significance and between group differences 
at either two-weeks post-taper or IS-weeks post-taper as was 
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predicted, although the differences were very close to 
conventional levels at .09 and .08, respectively. One 
possible explanation for this is that by 15-weeks post­
taper, 60% of the drug only group went back on alprazolam. 
Therefore, the benzodiazepine could have been alleviating 
the sensitivity to the physical symptoms which the ASI 
specifically tests. The subjects most likely were not 
feeling a rapip heart beat, as a result, they may have been 
temporarily -less fearful. While unavoidable, this was one 
problem with the study. It was, impossible to get a score on 
the ASI which accurately reflected the differences between 
the two groups when so many subjects went back on 
medication. However, the fact that 60% went back on 
alprazolam simply validates the importance of cognitive 
restructuring. 
Another problem with the study is that it lies upon the 
assumption that cognitive change will be accurately 
represented by the ACQ, ASI, and ECQ. These measurements 
have proven to be valid in assessing the cognitive 
symptomatology of panic disorder (Chambless, et al., 1984; 
McNally & Lorenz, 1987; Rapee et aI, 1989) however, the 
specific cognitive change may not always be accurately 
measured or indicated by the subjects' self report. In 
addition, while this study found cognitive change to be an 
essential component for panic disorder treatment, many other 
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factors can be responsible for unsuccessful discontinuation 
or relapse. For example, age of onset, duration of the 
disorder, previous medication use, stress, or personal 
experiences could all possibly affect subjects' inability to 
discontinue their medication. Yet these correlations have 
not yet been specifically addressed. In order to determine 
what, if any, external factors are associated with 
unsuccessful d~scontinuation or relapse, further research is 
necessary. 
Since the cognitive factors ~ere found to be a large 
component in the treatment of PDA, one implication could be 
that CBT be specifically targeted to provide the most 
beneficial cognitive restructuring techniques. In 
particular, it should be aimed at altering patients' 
sensitivity to bodily sensations and lowering their overall 
level of anxiety. In addition, it should work at modifying 
patients' perceived levels of emotional control and their 
catastrophic thinking. This specific emphasis in cognitive 
restructuring could facilitate benzodiazepine 
discontinuation and reduce relapse rates. The 
specialization of CBT and the creation of similar mechanisms 
would be beneficial to test in further research. 
Perhaps the ASI and the HAT could be used prior to 
tapering patients off medication in order to determine if 
they are less sensitive to their bodily sensations and are 
-23 
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experiencing a decrease in overall anxiety. If not, they 
may not be able to deal with the withdrawal symptoms which 
may arise. For example, if after 12 weeks of alprazolam and 
CBT a patient is still very sensitive to his bodily 
sensations and still experiencing an anxious mood, he will 
not be able, or ready, to successfully discontinue 
medication. Thus, he should not be taken off the drug. 
Further researCh testing the use of these two measures as 
determinants or regulatory mechanisms is imperative. 
Overall, the study puts fort~ the idea that 
benzodiazepine discontinuation involves more than just a 
decrease in drug dosage. Cognitive factors and level of 
anxious mood seem to play a major role in predicting who can 
successfully discontinue drug therapy and remain off the 
medication. Benzodiazepine treatment may stop the symptoms 
of the disorder, but it does not reduce the actual fear. 
When used alone, it only leads to avoidance. Unless the 
patients have a significant amount of cognitive 
restructuring, via CBT or another agent, relapse is likely 
to occur. The discontinuation process must consider both 
the biological and cognitive factors which occur among 
patients from pre-treatment, through discontinuation, and 
into the following months. If subjects are still 
experiencing and anxious mood and are fearful of their 
bodily sensations, this is a strong indication of relapse 
..
 
Cognitive Change 
24 
and unsuccessful discontinuation. Treatment plans whethert 
they incorporate a form of CBT or another mechanism, need to 
keep these results in mind. In conclusion, this study 
targets specific cognitive features of PDA and makes 
substantial suggestions for improving both benzodiazepine 
discontinuation and treatment intervention. 
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Appendix A 
----
ANXIETY SENSITIVITY INDEX
 
Name:
 
Age: Date: Sex: M F_"_"_
 
Listed below are a number of statements describing a set of beliefs~ 
Please read each statement carefully and, on the 0-5 scale given, indicate 
how much you think each statement is typical of you. 
-----0-----------1-----------2-----------3-----------4-----------5----­
Strongly Moderately Slightly Slightly Moderately Strongly
 
Disagree Disagree Disagree Agree Agree Agree
 
l-	 It is. important to me not to appear nervous. 
2.	 When I cannot keep my mind on a task, I worry that I might be 
going crazy. 
3.	 It scares me when I feel 'shaky' (trembling) • 
---'-­
4.	 It scares me when I feel faint. 
5.	 It is important to me to stay in control of my emotions. 
6.	 It scares me when my heart beats rapidly. 
7.	 It embarrasses me when my stomach growls. 
8.	 It scares me when I am nauseous. 
9.	 When I notice that my heart is beating rapidly, I worry that I 
might have a heart attack. 
10. It scares me when I become short of breath. 
11. When my stomach is upset, I worry that I might be seriously ill. 
12. It scares me when I am unable to keep my mind on a task. 
13. Other people notice when I feel shaky. 
14. Unusual body sensations scare me. 
15. When I am nervous, I worry that I might be mentally ill. 
_____16. It scares me when I am nervous. 
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Appendix B 
-_NarDe:
--'-----'------------
r:ate: 
Felow are sane'thalghts or ideas that may pass throogh peq:>le's ltli.ms when 
they are nervous or frightene::l. Please rate how often each thooght occurs 
to you when you are nervous. 0:> this, by writirg the apprq>riate number 
fran the followi.--g scale in the space next to the thought. 
1. 'lhought never oa:urs. 
2. '1hcught rarely oa:urs. 
3. 'lba.1ght occurs durirg half of the times I am nervoos. 
4. 'Iholght usually occurs. 
5. 'lhought aiways occurs when I am neJ:Voos. 
I am goi.rq to throw uP. 
I· am goi.rq to pass rot. 
I must have a brain tum:>r. 
I will have a heart attack. 
I will choke to death. 
I am goi.rq to act foolish. 
I am goi.rq blin:I. 
I will not be able to control myself. 
I will hurt saneone. 
I am goi.rq to have a stroke. 
I am goi.rq to go crazy. 
I am goirq to scream. 
I am goirq to babble or talk fLmny. 
I will be paralyzed by fear. 
other ideas rot listed (please describe an:i rate them) • 
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Appendix C 
-__
Name:
 
Age: Date:_"""'--_----:~ _ "sex: M F
 
Listed bel""" are a number of statements describirg a set of beliefs. 
Please read each statement carefully ani, on the 0-5 scale given, irdicate 
heM nuch you think ~ statement is typical of you. 
--0---1 ----2------3-----4-----5­
Strongly M:xlerately Slightly Slightly Moderately Strongly 
Disagree Disagree Disagree Agree Agree Agree 
_1.	 I can" o:>ntrol the degree to which I react to particular
 
situations .
 
." 
____2. H""" well I cope with difficult situations deperx:1s on whether I 
have outside help.. 
When I am p.rt \1l"rler stress, I am likely to lose o:>ntrol.---~) 
--
4.	 I can eaSily tum a difficult situation into a manageable one. 
.' 
---...~,	 My errotions seem to have a life of their own. 
6. I can deal successfully with stressful situations. 
----..l 7,- Whether I can successfully escape a fright.en:irq situation is 
always a matter of chance with lI'e. 
8. I can usually influence the degree to which a situation is 
~amtially~~toll'e. 
9,~ 
'Ihe degree to which I react to prebleIt'S is out of my o:>ntrol. 
...--lev. 'Ihe extent to which a difficult situation resolves itself has 
nothi.n1 to do with my actions. 
___...1],.. 'Ihere is noth..ing I can do to stop anxiety once it has started. 
__ J.2~ Any little th..ing can make lI'e uptight. 
13 . I feel like I am the victim of my em:Jtions. 
14 . I am able to control my level of anxiety. 
15. I am able to prevent myself from becorni.rq overly anxious. 
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Table 1 
Differences Between the A+CBT and A-Only groups at Two-weeks 
Post-taper and 15-weeks Post-taper 
Major Assessments 
Measures Baseline 2-wks post-taper 15-wks post-taper 
A+CBT A-Only A+CBT P A-Only A+CBT E A-Only 
Disability 
Monthly Average 1.97 1.95 .73 .04 1.43 .48 .03 2.97 
Anticipatory Anxiety 
Frequency (week) 
Intensity 
5.30 
3.10 
6.70 
3.70 
1.00 
2.30 
.02 
.29 
6.80 
3.50 
.40 
1.00 
.03 
.03 
11.60 
3.60 
Anxious Mood 
Hamilton Anxiety Scale 10.70 9.40 10.40 .10 14.60 6.30 .02 15.30 
Depressed Mood 
Beck Depression Inventory 7.50 7.60 4.50 .22 7.60 2.50 .04 9.90 
Catastrophic Thinking 
Agoraphobic Cog. Ques. 1.91 2.11 1.39 .003 2.00 1.29 .006 2.02 
Fear of Anxiety Sensations 
Anxiety Sensitivtiy Index 39.00 47.90 29.70 .09 42.90 24.80 .08 42.00 
Emotional Control 
Emotional Control Ques. 46.60 44.20 55.30 .04 44.50 59.05 .009 40.60 
Note. A+CBT = Alprazolam plus Cognitive Behavior Therapy;
 
A-Only = Alprazolam Only; P = Significance Level (p<.05).
 
